Element Science News Today

This randomized trial compares the effect of intermediate-dose vs standard prophylactic enoxaparin on a composite outcome of acute venous thromboembolism (VTE),

Element Science announced positive data from a study of its Jewel patch-wearable cardioverter defibrillator (P-WCD).

Were the GLP-1 receptor agonist drugs apparent benefits in STEP-HFpEF due solely to weight loss or additional mechanisms? The trial offers a clue, experts say.

At a glance:

Bristol Myers Squibb in collaboration with Janssen Pharmaceuticals announced all three prospective antithrombotic indications for milvexian have received fast track designation from the FDA. The designation covers all three phase 3 Librexia development studies of the investigational oral factor XIa inhibitor: Librexia Stroke, Librexia ACS and Librexia AF. According to a company press release, the

Stanford researchers lay out a framework for engineers as they expand and build new medical artificial intelligence models.

The procedures success seemed to depend on dosage, patient age, and type of cardiac surgery in this small phase-2 study with a sham-control group.

The powerful LDL-lowering agents arent being used to their fullest potential, but giving them early to STEMI patients along with high-intensity statins would help amend that, researchers say.

Although interest in renal denervation in hypertension fell off after disappointing results from the 2014 trial, a new, longer-term analysis argues the treatment may have worked after all.

This modeling study estimates the excess deaths attributable to COVID-19 disease in Massachusetts during the Delta (June to December 2021) and Omicron (December